170 related articles for article (PubMed ID: 32826248)
21. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements.
Catalona WJ; Smith DS; Ornstein DK
JAMA; 1997 May; 277(18):1452-5. PubMed ID: 9145717
[TBL] [Abstract][Full Text] [Related]
22. The U Shape of Prostate-specific Antigen and Prostate Cancer-specific Mortality in High-grade Metastatic Prostate Adenocarcinoma.
Wang J; Abudurexiti M; Shao N; Wei Y; Zhu Y; Ye DW
Eur Urol Focus; 2020 Jan; 6(1):53-62. PubMed ID: 30217630
[TBL] [Abstract][Full Text] [Related]
23. Metabolic syndrome is associated with high grade Gleason score when prostate cancer is diagnosed on biopsy.
De Nunzio C; Freedland SJ; Miano R; Trucchi A; Cantiani A; Carluccini A; Tubaro A
Prostate; 2011 Oct; 71(14):1492-8. PubMed ID: 21360562
[TBL] [Abstract][Full Text] [Related]
24. Prostate cancer screening in Tyrol, Austria: experience and results.
Horninger W; Reissigl A; Rogatsch H; Volgger H; Studen M; Klocker H; Bartsch G
Eur Urol; 1999; 35(5-6):523-38. PubMed ID: 10325519
[TBL] [Abstract][Full Text] [Related]
25. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
26. Characteristics of Prostate Cancer by Opportunistic Screening in Korean Men with a Prostate-Specific Antigen Level Less Than 4.0 ng per Milliliter.
Choi H; Cho S; Bae JH; Lee SE; Hong SK; Moon DG; Cheon J; Byun SS; Park JY
Urol Int; 2017; 99(2):143-148. PubMed ID: 28395285
[TBL] [Abstract][Full Text] [Related]
27. Grade groups at diagnosis in African Caribbean men with prostate cancer: Results of a comparative study.
Meunier ME; Tantot J; Neuzillet Y; Ghoneim TP; Martin F; Taouil T; Vignac M; Baumert H; Vinh-Hung V; Dussaule-Duchatelle V; Lebret T; Sutter W; Molinié V
Prostate; 2019 Oct; 79(14):1640-1646. PubMed ID: 31376218
[TBL] [Abstract][Full Text] [Related]
28. Association of very low prostate-specific antigen levels with increased cancer-specific death in men with high-grade prostate cancer.
Mahal BA; Aizer AA; Efstathiou JA; Nguyen PL
Cancer; 2016 Jan; 122(1):78-83. PubMed ID: 26371600
[TBL] [Abstract][Full Text] [Related]
29. Importance of prostate-specific antigen (PSA) as a predictive factor for concordance between the Gleason scores of prostate biopsies and RADICAL prostatectomy specimens.
Lima NG; Soares Dde F; Rhoden EL
Clinics (Sao Paulo); 2013 Jun; 68(6):820-4. PubMed ID: 23778496
[TBL] [Abstract][Full Text] [Related]
30. Predictors of first repeat biopsy cancer detection with suspected local stage prostate cancer.
Fowler JE; Bigler SA; Miles D; Yalkut DA
J Urol; 2000 Mar; 163(3):813-8. PubMed ID: 10687983
[TBL] [Abstract][Full Text] [Related]
31. The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume.
Corcoran NM; Casey RG; Hong MK; Pedersen J; Connolly S; Peters J; Harewood L; Gleave ME; Costello AJ; Hovens CM; Goldenberg SL
BJU Int; 2012 Jul; 110(1):36-42. PubMed ID: 22085203
[TBL] [Abstract][Full Text] [Related]
32. Evaluating the Four Kallikrein Panel of the 4Kscore for Prediction of High-grade Prostate Cancer in Men in the Canary Prostate Active Surveillance Study.
Lin DW; Newcomb LF; Brown MD; Sjoberg DD; Dong Y; Brooks JD; Carroll PR; Cooperberg M; Dash A; Ellis WJ; Fabrizio M; Gleave ME; Morgan TM; Nelson PS; Thompson IM; Wagner AA; Zheng Y;
Eur Urol; 2017 Sep; 72(3):448-454. PubMed ID: 27889277
[TBL] [Abstract][Full Text] [Related]
33. The cost-effectiveness of prostate cancer screening using the Stockholm3 test.
Karlsson AA; Hao S; Jauhiainen A; Elfström KM; Egevad L; Nordström T; Heintz E; Clements MS
PLoS One; 2021; 16(2):e0246674. PubMed ID: 33630863
[TBL] [Abstract][Full Text] [Related]
34. The Clinical Course of Patients With Prostate-Specific Antigen ≥100 ng/ml: Insight Into a Potential Population for Targeted Prostate-Specific Antigen Screening.
Leung AK; Hugar L; Patil D; Wong L; Carthon B; Carney KJ; Birdsong G; Moses KA; Master VA
Urology; 2018 Jul; 117():101-107. PubMed ID: 29656066
[TBL] [Abstract][Full Text] [Related]
35. Percent free prostate-specific antigen is effective to predict prostate biopsy outcome in Chinese men with prostate-specific antigen between 10.1 and 20.0 ng ml(-1).
Chen R; Zhou LQ; Cai XB; Xie LP; Huang YR; He DL; Gao X; Xu CL; Ding Q; Wei Q; Yin CJ; Ren SC; Wang FB; Tian Y; Sun ZQ; Fu Q; Ma LL; Zheng JH; Ye ZQ; Ye DW; Xu DF; Hou JQ; Xu KX; Yuan JL; Gao X; Liu CX; Pan TJ; Sun YH;
Asian J Androl; 2015; 17(6):1017-21. PubMed ID: 25926603
[TBL] [Abstract][Full Text] [Related]
36. High Gleason scores and lower prostate-specific antigen levels in a single institution over the past decade.
Abouelfadel Z; Miller GJ; Glode LM; Akduman B; Donohue RE; Nedrow A; Crawford ED
Clin Prostate Cancer; 2002 Sep; 1(2):115-7. PubMed ID: 15046702
[TBL] [Abstract][Full Text] [Related]
37. Prostate cancer screening by prostate-specific antigen (PSA); a relevant approach for the small population of the Cayman Islands.
Jyoti SK; Blacke C; Patil P; Amblihalli VP; Nicholson A
Cancer Causes Control; 2018 Jan; 29(1):87-92. PubMed ID: 28918559
[TBL] [Abstract][Full Text] [Related]
38. Comparison between clinical significance of serum proinflammatory protein interleukin-6 and classic tumor markers total PSA, free PSA and free/total PSA prior to prostate biopsy.
Milicević N; Mrcela M; Lukić I; Mandić S; Horvat V; Galić J
Coll Antropol; 2014 Mar; 38(1):147-50. PubMed ID: 24851609
[TBL] [Abstract][Full Text] [Related]
39. Serum insulin level, disease stage, prostate specific antigen (PSA) and Gleason score in prostate cancer.
Lehrer S; Diamond EJ; Stagger S; Stone NN; Stock RG
Br J Cancer; 2002 Sep; 87(7):726-8. PubMed ID: 12232754
[TBL] [Abstract][Full Text] [Related]
40. Impact of race on prostate-specific antigen outcome after radical prostatectomy for clinically localized adenocarcinoma of the prostate.
Cross CK; Shultz D; Malkowicz SB; Huang WC; Whittington R; Tomaszewski JE; Renshaw AA; Richie JP; D'Amico AV
J Clin Oncol; 2002 Jun; 20(12):2863-8. PubMed ID: 12065563
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
